

Press Release

MEDICA S.P.A.

FIRST DAY OF TRADING ON EURONEXT GROWTH MILAN

Medolla (MO), 3 November 2021 – Medica S.p.A., fully integrated Italian biomedical and MedTech group with a strong international footprint, announces today that its shares are now listed on *Euronext Growth Milan*, multilateral trading facility organized and managed by Borsa Italiana S.p.A..

The first day of trading for Medica S.p.A. shares registered an opening price of 36.0 Euro, reaching a maximum price of 38.0 Euro, and concluded the session at an official price of 33.45 Euro, up by 23.9% compared to the placement price of 27.0 Euro per share.

The number of shares traded during the first day was over 210 thousand, for an equivalent value of about 7.4 million Euros.

Medica listing process saw Intesa Sanpaolo (IMI Corporate & Investment Banking Division) as Global Coordinator & Joint Bookrunner, CFO SIM as Joint Bookrunner and *Euronext Growth Advisor*, DLA Piper as Issuer's Law Firm, LCA Studio Legale as Joint Bookrunners' Law Firm, Epyon as Advisor for Financial Due Diligence, Non-accounting Data and Management Information System, EY as Independent Audit Firm, and Hermes as Business Plan Advisor and Advisor for Tax Due Diligence.

Medica Group is operating since 1985 in the biomedical district of Mirandola (Italy). Development of innovative products for blood purification has always been company's core business. Thanks to the activity of two extremely dynamic R&D groups (medical equipment, membranes and disposable), the Group competes successfully in several markets, namely:

- **Medical** (dialysis, CRRT, ECCO2, Apheresis, DFPP, CHF, HIPEC, pre-transplant organ perfusion, bioregenerative medicine, gastroenterology, urodynamics, oxygen humidification).
- **Microbiological purification of water**
- **Industrial automation** for the biomedical sector.

R&D focus has been integrated over the years with a highly automated production systems in five different facilities, four in Italy and one in Tunisia, and two commercial entities (in US and in China).

The key success factors of the Group are:

- **extrusion of hollow fiber membranes** for hemofiltration, plasmapheresis, cascade filtration, oxygen humidification, ultrafiltration and microfiltration of water
- **vertical integration**, proved by the ability to manage not only the design and development of medical disposables and equipment, and the development of the automation technologies required for their production as well.

- **International recognition with significant share of export** (69% of revenues in 2020), with sales in over 60 countries.

Medica group closed the consolidated financial statement for the year 2020 with revenues of 44.1 million euros (34.7 million euros in 2019), EBITDA of 9.5 million euros (7.7 million euros in 2019), EBIT of 5.6 million euros (3.6 million euros in 2019) and net profit of 3.8 million euros (2.8 million euros in 2019). In the first 6 months of 2021, Medica realized revenues of 20.3 million euros and an EBITDA of 4.2 million euros.

For information:

Investor Relations Medica

Giovanni Plasmati

(+39) 0535 51159

giovanni.plasmati@medica.it

Euronext Growth Advisor

CFO SIM S.p.A.

(+39) 02 303431

ecm@cfosim.com